Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:AVGR NASDAQ:ELGX NASDAQ:OBLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.85+0.2%$0.86$0.55▼$1.66$109.25M0.9757,687 shs432,504 shsAVGRAvinger$0.47$0.47$0.36▼$1.93$1.57M1.291.36 million shsN/AELGXEndologix$0.07$0.03$0.22▼$7.10$1.41M0.731.28 million shs85,372 shsOBLNObalon Therapeutics$2.38+0.4%$4.22$0.66▼$10.77$23.85M-1.237.68 million shs105,133 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics+2.27%+1.90%-6.03%+43.09%-22.40%AVGRAvinger0.00%0.00%0.00%0.00%-72.84%ELGXEndologix0.00%0.00%0.00%0.00%0.00%OBLNObalon Therapeutics0.00%-2.87%-43.30%+446.97%+1,049.37%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Genetics1.6012 of 5 stars3.71.00.00.01.11.70.0AVGRAvingerN/AN/AN/AN/AN/AN/AN/AN/AELGXEndologixN/AN/AN/AN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 3.33Buy$6.17630.04% UpsideAVGRAvinger 0.00N/AN/AN/AELGXEndologix 0.00N/AN/AN/AOBLNObalon Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ATOS, OBLN, AVGR, and ELGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025ATOSAtossa GeneticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.25 ➝ $7.506/5/2025ATOSAtossa GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$4.004/21/2025ATOSAtossa GeneticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.25(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/AAVGRAvinger$7.65M0.21N/AN/A($4.53) per share-0.10ELGXEndologix$143.37M0.01N/AN/A$3.56 per share0.02OBLNObalon Therapeutics$1.59M15.00N/AN/A$0.60 per share3.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.21N/AN/AN/AN/A-33.90%-31.53%8/11/2025 (Estimated)AVGRAvinger-$18.32M-$11.06N/AN/AN/AN/AN/AN/A8/6/2025 (Estimated)ELGXEndologix-$64.76M-$2.19N/AN/AN/A-44.65%-63.96%-13.26%N/AOBLNObalon Therapeutics-$12.33MN/AN/A∞N/A-776.76%-161.38%-83.58%N/ALatest ATOS, OBLN, AVGR, and ELGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ATOSAtossa Genetics-$0.06-$0.05+$0.01-$0.05N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/AAVGRAvingerN/AN/AN/AN/AN/AELGXEndologixN/AN/AN/AN/AN/AOBLNObalon TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A12.6712.67AVGRAvingerN/AN/AN/AELGXEndologix0.290.390.28OBLNObalon TherapeuticsN/A1.861.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%AVGRAvinger18.30%ELGXEndologix51.61%OBLNObalon Therapeutics18.64%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics8.70%AVGRAvinger42.80%ELGXEndologix1.30%OBLNObalon Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million117.93 millionOptionableAVGRAvinger703.31 million1.89 millionNot OptionableELGXEndologix52819.17 millionN/AOptionableOBLNObalon Therapeutics210.02 millionN/ANot OptionableATOS, OBLN, AVGR, and ELGX HeadlinesRecent News About These CompaniesInterWest Management Partners X, LLC's Net WorthAugust 4, 2024 | benzinga.comObalon Therapeutics, Inc.February 25, 2024 | thestreet.comSpero Therapeutics Inc.February 6, 2024 | wsj.comIntragastric Balloon Market Growth and Forecast till 2031March 28, 2023 | marketwatch.comIntragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 PagesAugust 17, 2022 | marketwatch.comRenovare Environmental Inc (RENO)January 5, 2022 | investing.comUnderstanding Atara Biotherapeutics's Unusual Options ActivityAugust 10, 2021 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge PotentialATOS, OBLN, AVGR, and ELGX Company DescriptionsAtossa Genetics NASDAQ:ATOS$0.85 +0.00 (+0.17%) Closing price 04:00 PM EasternExtended Trading$0.85 +0.00 (+0.33%) As of 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.Avinger NASDAQ:AVGR$0.47 0.00 (0.00%) As of 07/1/2025Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. Its lumivascular products comprise Lightbox imaging consoles; the Ocelot and Tigereye family of devices, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. The company is also developing IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is based in Redwood City, California.Endologix NASDAQ:ELGXEndologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.Obalon Therapeutics NASDAQ:OBLNObalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
